Expert Review of Cardiovascular Therapy最新文献_第3页

Tricuspid transcatheter edge-to-edge repair versus surgery for tricuspid regurgitation: a systematic review and meta-analysis. 三尖瓣经导管边缘对边缘修复与手术治疗三尖瓣反流：一项系统回顾和荟萃分析。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI: 10.1080/14779072.2025.2549018

Michail Penteris, Konstantinos Lampropoulos

{"title":"Tricuspid transcatheter edge-to-edge repair versus surgery for tricuspid regurgitation: a systematic review and meta-analysis.","authors":"Michail Penteris, Konstantinos Lampropoulos","doi":"10.1080/14779072.2025.2549018","DOIUrl":"10.1080/14779072.2025.2549018","url":null,"abstract":"Introduction: To perform a systematic review and meta-analysis to compare the safety, early and late mortality, morbidity and long-term function of the tricuspid valve (TV) following tricuspid transcatheter edge-to-edge repair (T-TEER) compared to surgical tricuspid valve (TV) repair/replacement (TVR) for tricuspid regurgitation (TR).Methods: This review investigates through two different databases for original studies that evaluated patients with TR who underwent either T-TEER or TVR was until December 2024. The outcomes of interest were safety, morbidity, mortality and long-term function following T-TEER vs TVR.Results: We identified three retrospective observational studies, including a total of 1612 patients with TR. Short-term (OR, 0.36; 95% CI, 0.13-1.04; p = 0.06) and long-term mortality was similar between T-TEER and TVR. There was a lower risk of acute kidney injury (AKI) (OR, 0.31; 95% CI, 0.23-0.43; p < 0.00001) and permanent pacemaker implantation (PPI) (OR, 0.19; 95% CI, 0.10-0.35; p < 0.00001) with T-TEER, while there was no significant difference in terms of stroke events (OR, 1.17; 95% CI, 0.68-2.01; p = 0.58) and risk of bleeding (OR, 0.81; 95% CI, 0.45-1.44; p = 0.47) compared to TVR.Conclusions: In conclusion, T-TEER appears to have a comparable safety profile to TVR with a lower risk of AKI and PPI. However, these findings are based on limited observational data and should be interpreted as hypothesis-generating rather than conclusive.Registration: This systematic review and meta-analysis was prospectively registered on the international prospective register of systematic reviews (PROSPERO; CRD42024622555).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":"23 9","pages":"567-575"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the importance of understanding heart disease causes in nonischemic and ischemic cardiomyopathy for left ventricular thrombus patients? 了解左室血栓患者的非缺血性和缺血性心肌病病因的重要性是什么？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-08 DOI: 10.1080/14779072.2025.2544824

Masashi Fujino, Teruo Noguchi

引用次数: 0

High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines. 高apoB/apoA-1比值是主要心脑血管不良事件的一个强有力的风险预测因子。第一部分：更新指南的回顾基础

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-27 DOI: 10.1080/14779072.2025.2543537

Göran Walldius

{"title":"High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines.","authors":"Göran Walldius","doi":"10.1080/14779072.2025.2543537","DOIUrl":"10.1080/14779072.2025.2543537","url":null,"abstract":"Introduction: Hypercholesterolemia and other dyslipidemias are common risk factors for cardiovascular diseases (CVD) and development of atherosclerosis. International guidelines recommend LDL-C, non-HDL-C and apoB under some conditions for clinical use in evaluating risk of CVD. In part 1 of this review newer risk factor data for apoA-1, and the apoB/apoA-1 ratio is presented for cardiovascular, cerebrovascular, diabetes and other CVD manifestations of atherosclerosis. Compared to conventional lipids, these apolipoproteins add strong clinical risk information for these CVD disorders and for a range of other diseases.Areas covered: Prospective studies, reviews, meta-analyses, case control, nested-case and therapeutic studies are analyzed. Searches were conducted with Google and in PubMed, and CVD journals for peer-reviewed publications. In part 2 of this review newer risk factor data for apoA-1, and the apoB/apoA-1 ratio is presented for atherosclerotic plaques, HDL-C versus apoA-1, inflammatory diseases, cancer, and metastases.Expert opinion: Associations between apoB, apoA-1 and especially the apoB/apoA-1 ratio and development of atherosclerosis related risk of multiple CVD diseases have been documented world-wide. This data indicates that the balance, i.e. the ratio between the atherogenic apoB and the protective apoA-1, significantly improves risk evaluation and prediction of CVD, hence calling for an update of guidelines.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"521-545"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 2: a review basis for updating guidelines. 高apoB/apoA-1比值是主要心脑血管不良事件的一个强有力的风险预测因子。第2部分：更新指南的回顾基础

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-08 DOI: 10.1080/14779072.2025.2543535

Göran Walldius

{"title":"High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 2: a review basis for updating guidelines.","authors":"Göran Walldius","doi":"10.1080/14779072.2025.2543535","DOIUrl":"10.1080/14779072.2025.2543535","url":null,"abstract":"Introduction: Hypercholesterolemia and other dyslipidemias are common risk factors for cardiovascular diseases (CVD) and development of atherosclerosis. International guidelines recommend LDL-C, non-HDL-C, and apoB under some conditions for clinical use in evaluating risk of CVD. In part 2 of this review, newer risk factor data for apoA-1, and the apoB/apoA-1 ratio is presented for atherosclerotic plaques, HDL-C versus apoA-1, inflammatory diseases, cancer, and metastases. Compared to conventional lipids, these apolipoproteins add strong clinical risk information for these CVD disorders and for a range of other diseases.Areas covered: Prospective studies, reviews, meta-analyses, case control, nested-case, and therapeutic studies are analyzed. Searches were conducted with Google and in PubMed, and CVD journals for peer-reviewed publications. In part 1 of this review, newer risk factor data for apoA-1 and the apoB/apoA-1 ratio are presented for cardiovascular, cerebrovascular, diabetes, and other CVD manifestations of atherosclerosis.Expert opinion: Strong associations between apoB, apoA-1 and especially the apoB/apoA-1 ratio and development of atherosclerosis-related risk of multiple CVD diseases have been documented world-wide. These data indicate that the balance, i.e. the ratio between the atherogenic apoB and the protective apoA-1, significantly improves risk evaluation and prediction of CVD, hence calling for an update of guidelines.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"547-566"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term exposure to air pollution and coronary atherosclerosis: understanding the correlation. 长期暴露于空气污染和冠状动脉粥样硬化：了解相关性。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-09-01 Epub Date: 2025-08-26 DOI: 10.1080/14779072.2025.2549016

Tomasz Urbanowicz

引用次数: 0

Cardiovascular and periprocedural outcomes of endovascular intervention for acute limb ischemia at experienced urban versus rural centers in the US: national inpatient sample analysis 2016-2021. 美国经验丰富的城市和农村中心血管内介入治疗急性肢体缺血的心血管和围手术期结果：2016-2021年全国住院患者样本分析

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-11 DOI: 10.1080/14779072.2025.2527707

Yasar Sattar, Adishwar Rao, Sivaram Neppala, Himaja Dutt Chigurupati, Waleed Alruwaili, Hafeez Ul Hassan Virk, Fadi Saab, Jihad Mustapha, Abdullah Naveed Muhammad, Ramesh Daggubati, Akram Kawsara

{"title":"Cardiovascular and periprocedural outcomes of endovascular intervention for acute limb ischemia at experienced urban versus rural centers in the US: national inpatient sample analysis 2016-2021.","authors":"Yasar Sattar, Adishwar Rao, Sivaram Neppala, Himaja Dutt Chigurupati, Waleed Alruwaili, Hafeez Ul Hassan Virk, Fadi Saab, Jihad Mustapha, Abdullah Naveed Muhammad, Ramesh Daggubati, Akram Kawsara","doi":"10.1080/14779072.2025.2527707","DOIUrl":"10.1080/14779072.2025.2527707","url":null,"abstract":"Background: Acute limb ischemia (ALI) is a critical vascular emergency marked by a sudden reduction in blood flow to the limb, significantly increasing amputation risk. Revascularization outcomes in urban versus rural areas have not been examined.Research design and methods: The National Inpatient Sample from 2016 to 2021 identified patients with ALI who underwent revascularization. Propensity score matching compared outcomes, analyzed using STATA version 18.Results: Of 85,760 hospitalizations for ALI receiving percutaneous revascularization 81,880 (95.5%) were in urban centers and 3,880 (4.5%) in rural facilities. Patients in urban hospitals showed higher mortality (4% vs. 2.7%), myocardial infarction (MI) (3.4% vs. 2.7%), cardiogenic shock (1.6% vs. 0.6%), cardiac arrest (6.5% vs. 5.9%), major adverse cardiovascular and cerebrovascular events (MACCE) (7.5% vs. 5.3%), mechanical circulatory support (1.1% vs. 0.5%), and acute kidney injury (18.5% vs. 15.4%). However, urban patients had lower intravascular ultrasound (IVUS) (3.4% vs. 6.5%), major amputation (6.3% vs. 7.8%), fasciotomy (1.8% vs. 2.2%), and major adverse limb events (MALE) (46.4% vs. 49.1%), with a significant difference of p < 0.01 compared to rural hospitals.Conclusions: Urban hospitals in the United States report elevated mortality rates and significant cardiovascular events in comparison to their rural counterparts.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A scoping review of factors associated with the prescribing choice of direct oral anticoagulant drugs. 与直接口服抗凝药物处方选择相关因素的范围审查。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-25 DOI: 10.1080/14779072.2025.2536043

Hanan Abunimeh, Solafa NoorSaeed, Rahaf Alkhlaifat, Amanj Kurdi, Tanja Mueller

{"title":"A scoping review of factors associated with the prescribing choice of direct oral anticoagulant drugs.","authors":"Hanan Abunimeh, Solafa NoorSaeed, Rahaf Alkhlaifat, Amanj Kurdi, Tanja Mueller","doi":"10.1080/14779072.2025.2536043","DOIUrl":"10.1080/14779072.2025.2536043","url":null,"abstract":"Introduction: With the substantial increase in direct oral anticoagulant (DOAC) usage, prescribers face complex decisions regarding the appropriate agent selection. This scoping review aimed to identify factors influencing oral anticoagulant choice in clinical practice over time.Methods: Four databases (Medline, Embase, Scopus, Web of Science) were searched for quantitative observational studies on patients prescribed DOACs for any indication, focusing on factors affecting OAC choice. Studies published from January 2010 to March 2023 were included.Results: Of the 4659 identified studies, 60 met selection criteria. Most (96%) examined the choice between DOACs and vitamin K antagonists (VKA); while (15%) evaluated factors affecting choice among DOACs. Age and gender were included in 77% and 70% of studies, respectively. Renal impairment (58%), heart failure (48%), previous stroke (43%), and thromboembolic risk (43%) were also commonly assessed. Older age had a significant negative association with DOAC prescribing in (50%) of the studies; renal impairment reduced DOAC initiation, favoring warfarin in (94%).Conclusions: Several significant key factors were identified as being associated with OAC choice, including demographic factors such as age, and clinical factors such as kidney function, prior stroke, and other comorbidities. Significant factors in the choice among DOACs were advanced age, and renal impairment.Registration: This systematic review was registered as a PURE protocol (https://pureportal.strath.ac.uk/en/projects/factors-associated-with-the-prescribing-of-direct-acting-oral-ant).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"427-445"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical differences among types of in-stent calcifications in coronary arteries: how can this be better managed? 冠状动脉支架内钙化类型的临床差异：如何更好地处理？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-14 DOI: 10.1080/14779072.2025.2534715

Hiroyuki Jinnouchi, Kenichi Sakakura, Hideo Fujita

{"title":"Clinical differences among types of in-stent calcifications in coronary arteries: how can this be better managed?","authors":"Hiroyuki Jinnouchi, Kenichi Sakakura, Hideo Fujita","doi":"10.1080/14779072.2025.2534715","DOIUrl":"10.1080/14779072.2025.2534715","url":null,"abstract":"Introduction: In-stent calcification is recognized as a significant contributor to unfavorable clinical outcomes. Understanding the various types and underlying mechanisms of in-stent calcification can help interventional operators to make decisions.Areas covered: This review will describe the distinct types of in-stent calcification, which are categorized into in-stent smooth calcification and in-stent calcified nodule. The mechanisms and characteristics of in-stent smooth calcification and calcified nodule will be summarized. Given the differences between these two types, treatment approaches will be discussed. This review will focus on histopathology and intracoronary imaging. For the purpose of this review, evidence was gathered from electronic literature searches via PubMed, with a particular focus on primary evidence published in the last 5 years.Expert opinion: Several treatment devices are available such as conventional balloon, modified balloon, atherectomy device, and intravascular lithotripsy. In-stent smooth calcification and calcified nodule might result in different clinical courses after repeated target lesion revascularization. Understanding the mechanisms with the various types of in-stent calcification may assist operators in selecting appropriate treatment strategies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"377-388"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical utility of platelet FcγRIIa as a cardiovascular risk marker in patients in acute myocardial infarction. 血小板fc - γ riia作为急性心肌梗死患者心血管危险标志物的临床应用

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-01 Epub Date: 2025-08-09 DOI: 10.1080/14779072.2025.2543541

Ahmad Hallak, Mark B Effron

引用次数: 0

How can clinicians reduce the risk of and manage severe aortic valve regurgitation manifesting as cardiogenic shock? 临床医生如何降低和处理表现为心源性休克的严重主动脉瓣反流的风险？

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2025-08-01 Epub Date: 2025-08-04 DOI: 10.1080/14779072.2025.2542838

Ana Paula Tagliari, Adriano Nunes Kochi

{"title":"How can clinicians reduce the risk of and manage severe aortic valve regurgitation manifesting as cardiogenic shock?","authors":"Ana Paula Tagliari, Adriano Nunes Kochi","doi":"10.1080/14779072.2025.2542838","DOIUrl":"10.1080/14779072.2025.2542838","url":null,"abstract":"Introduction: Severe aortic regurgitation is a progressive condition that can lead to cardiogenic shock, a life-threatening emergency associated with high morbidity and mortality.Areas covered: This article provides an updated review on how clinicians can diagnose, prevent, and manage aortic regurgitation presenting as cardiogenic shock, as well as discusses emerging technologies that have transformed the management of this condition.Expert opinion: Clinicians can reduce the risk of aortic regurgitation manifesting as cardiogenic shock through a combination of early diagnosis, vigilant monitoring, optimized medical management, and timely intervention. Advanced imaging modalities, such as echocardiography and computed cardiac tomography, are essential for assessing valve function and identifying high-risk patients before decompensation occurs. For patients at risk, early referral to a multidisciplinary Heart Team is crucial for determining the optimal intervention, whether surgical or transcatheter. Future advancements in transcatheter therapies, including dedicated devices for aortic valve replacement, hold promise for expanding treatment options for high-risk patients.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"405-413"},"PeriodicalIF":2.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0